

SPECIALTY GUIDELINE MANAGEMENT

KYPROLIS (carfilzomib)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. In combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
2. As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more prior lines of therapy.

B. Compendial Uses

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. **Multiple myeloma**

Authorization of 12 months may be granted for treatment of multiple myeloma.

B. **Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma**

Authorization of 12 months may be granted for treatment of Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

1. Kyprolis [package insert]. Thousand Oaks, CA: Onyx Pharmaceuticals, Inc.; May 2017.
2. The NCCN Drugs & Biologics Compendium® © 2017 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed October 17, 2017.
3. The NCCN Clinical Practice Guidelines in Oncology® Multiple Myeloma (Version 2.2018) © 2017 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed October 17, 2017.
4. The NCCN Clinical Practice Guidelines in Oncology® Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma (Version 1.2017) © 2016 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed October 18, 2017.